Omnicell Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Omnicell wird ein jährliches Gewinn- und Umsatzwachstum von 100.7% bzw. 6% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 100.1% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 7.5% betragen.

Wichtige Informationen

100.7%

Wachstumsrate der Gewinne

100.1%

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum	17.0%
Wachstumsrate der Einnahmen	6.0%
Zukünftige Eigenkapitalrendite	7.5%
Analystenabdeckung	Good
Zuletzt aktualisiert	21 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Omnicell, Inc. Just Beat EPS By 43%: Here's What Analysts Think Will Happen Next

Nov 02

Recent updates

Omnicell, Inc. Just Beat EPS By 43%: Here's What Analysts Think Will Happen Next

Nov 02

Omnicell, Inc.'s (NASDAQ:OMCL) Price Is Right But Growth Is Lacking After Shares Rocket 49%

Aug 02

Is There Now An Opportunity In Omnicell, Inc. (NASDAQ:OMCL)?

Jul 11

Benign Growth For Omnicell, Inc. (NASDAQ:OMCL) Underpins Its Share Price

Jun 16

Omnicell (NASDAQ:OMCL) Is Making Moderate Use Of Debt

May 25

An Intrinsic Calculation For Omnicell, Inc. (NASDAQ:OMCL) Suggests It's 29% Undervalued

Mar 28

Omnicell, Inc.'s (NASDAQ:OMCL) 25% Dip In Price Shows Sentiment Is Matching Revenues

Feb 29

Is It Too Late To Consider Buying Omnicell, Inc. (NASDAQ:OMCL)?

Feb 23

Omnicell Is Building A Strong Moat

Feb 22

Does Omnicell (NASDAQ:OMCL) Have A Healthy Balance Sheet?

Jan 15

Benign Growth For Omnicell, Inc. (NASDAQ:OMCL) Underpins Its Share Price

Dec 25

Is Omnicell, Inc. (NASDAQ:OMCL) Trading At A 48% Discount?

Dec 06

Omnicell, Inc. (NASDAQ:OMCL) Analysts Just Slashed Next Year's Revenue Estimates By 14%

Nov 10

Is There An Opportunity With Omnicell, Inc.'s (NASDAQ:OMCL) 27% Undervaluation?

Sep 06

Would Omnicell (NASDAQ:OMCL) Be Better Off With Less Debt?

Aug 08

Why Omnicell, Inc. (NASDAQ:OMCL) Could Be Worth Watching

Jul 02

A Look At The Fair Value Of Omnicell, Inc. (NASDAQ:OMCL)

Jun 08

Investors Could Be Concerned With Omnicell's (NASDAQ:OMCL) Returns On Capital

Apr 29

Is Omnicell (NASDAQ:OMCL) Using Too Much Debt?

Apr 11

At US$55.77, Is Omnicell, Inc. (NASDAQ:OMCL) Worth Looking At Closely?

Mar 23

Is There An Opportunity With Omnicell, Inc.'s (NASDAQ:OMCL) 42% Undervaluation?

Feb 28

Returns On Capital Are Showing Encouraging Signs At Omnicell (NASDAQ:OMCL)

Jan 15

We Think Omnicell (NASDAQ:OMCL) Can Stay On Top Of Its Debt

Jan 01

Is There An Opportunity With Omnicell, Inc.'s (NASDAQ:OMCL) 46% Undervaluation?

Nov 17

Analysts Just Slashed Their Omnicell, Inc. (NASDAQ:OMCL) EPS Numbers

Nov 03

Omnicell launches Specialty Pharmacy Services

Oct 11

Omnicell (NASDAQ:OMCL) Seems To Use Debt Quite Sensibly

Sep 30

Omnicell says advance services to drive profitable growth in long-run: Investor Day

Sep 20

Is Now An Opportune Moment To Examine Omnicell, Inc. (NASDAQ:OMCL)?

Sep 15

Omnicell (NASDAQ:OMCL) Might Have The Makings Of A Multi-Bagger

Aug 31

Omnicell reports Q2 earnings miss; reaffirms FY22 guidance and issues Q3 outlook

Aug 04

Are Investors Undervaluing Omnicell, Inc. (NASDAQ:OMCL) By 41%?

Aug 03

Omnicell Fails To Justify Inclusion In Long-Only, Equity-Focused Portfolio

Jul 21

We Ran A Stock Scan For Earnings Growth And Omnicell (NASDAQ:OMCL) Passed With Ease

Jun 27

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:OMCL - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	1,230	33	62	154	5
12/31/2025	1,163	24	32	133	9
12/31/2024	1,105	8	38	144	9
9/30/2024	1,064	-18	118	170	N/A
6/30/2024	1,080	-21	152	204	N/A
3/31/2024	1,103	-21	165	218	N/A
12/31/2023	1,147	-20	126	181	N/A
9/30/2023	1,186	-34	165	225	N/A
6/30/2023	1,235	-23	127	189	N/A
3/31/2023	1,268	-18	48	107	N/A
12/31/2022	1,296	6	17	78	N/A
9/30/2022	1,309	48	-5	55	N/A
6/30/2022	1,258	61	18	77	N/A
3/31/2022	1,199	72	98	158	N/A
12/31/2021	1,132	78	173	232	N/A
9/30/2021	1,070	80	195	249	N/A
6/30/2021	987	60	194	242	N/A
3/31/2021	914	35	164	218	N/A
12/31/2020	892	32	131	186	N/A
9/30/2020	891	38	86	144	N/A
6/30/2020	906	49	101	164	N/A
3/31/2020	924	69	85	144	N/A
12/31/2019	897	61	83	145	N/A
9/30/2019	860	54	98	158	N/A
6/30/2019	836	48	59	117	N/A
3/31/2019	807	38	55	112	N/A
12/31/2018	787	38	50	104	N/A
9/30/2018	772	54	8	61	N/A
6/30/2018	754	48	N/A	27	N/A
3/31/2018	747	44	N/A	16	N/A
12/31/2017	713	31	N/A	25	N/A
9/30/2017	688	-1	N/A	45	N/A
6/30/2017	678	-6	N/A	72	N/A
3/31/2017	670	-9	N/A	56	N/A
12/31/2016	696	10	N/A	50	N/A
9/30/2016	651	8	N/A	54	N/A
6/30/2016	599	14	N/A	40	N/A
3/31/2016	539	24	N/A	44	N/A
12/31/2015	485	31	N/A	38	N/A
9/30/2015	476	32	N/A	37	N/A
6/30/2015	463	32	N/A	50	N/A
3/31/2015	455	31	N/A	75	N/A
12/31/2014	441	31	N/A	65	N/A
9/30/2014	425	28	N/A	49	N/A
6/30/2014	407	29	N/A	59	N/A
3/31/2014	395	27	N/A	52	N/A
12/31/2013	381	24	N/A	55	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: OMCL wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (2.6%).

Ertrag vs. Markt: OMCL wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: OMCL wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: OMCLDie Einnahmen des Unternehmens (6% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (9% pro Jahr).

Hohe Wachstumseinnahmen: OMCLDie Einnahmen des Unternehmens (6% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: OMCLDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (7.5%).

Omnicell Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Omnicell, Inc. Just Beat EPS By 43%: Here's What Analysts Think Will Happen Next

Omnicell, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2024

Price target increased by 22% to US$54.71

Price target increased by 7.5% to US$45.00

Price target increased by 17% to US$38.29

Omnicell, Inc. Provides Earnings Guidance for the Third Quarter and Full Year 2024

Recent updates

Now 22% undervalued after recent price drop

Omnicell, Inc. Just Beat EPS By 43%: Here's What Analysts Think Will Happen Next

Omnicell, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2024

Omnicell Q3 Earnings: Look At The Growth Segment

Price target increased by 22% to US$54.71

Is It Time To Consider Buying Omnicell, Inc. (NASDAQ:OMCL)?

Price target increased by 7.5% to US$45.00

Omnicell, Inc. to Report Q3, 2024 Results on Oct 30, 2024

Is Omnicell (NASDAQ:OMCL) Using Too Much Debt?

Omnicell, Inc. Announces Central Med Automation Service

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Price target increased by 17% to US$38.29

Omnicell, Inc.'s (NASDAQ:OMCL) Price Is Right But Growth Is Lacking After Shares Rocket 49%

Omnicell, Inc. Provides Earnings Guidance for the Third Quarter and Full Year 2024

Omnicell, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Is There Now An Opportunity In Omnicell, Inc. (NASDAQ:OMCL)?

Benign Growth For Omnicell, Inc. (NASDAQ:OMCL) Underpins Its Share Price

Now 20% undervalued

Omnicell (NASDAQ:OMCL) Is Making Moderate Use Of Debt

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Omnicell, Inc. Announces XT Amplify

Omnicell, Inc. to Report Q1, 2024 Results on May 02, 2024

Omnicell, Inc., Annual General Meeting, May 21, 2024

An Intrinsic Calculation For Omnicell, Inc. (NASDAQ:OMCL) Suggests It's 29% Undervalued

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

New minor risk - Shareholder dilution

High number of new directors

Omnicell, Inc. Announces Executive Changes

Omnicell, Inc.'s (NASDAQ:OMCL) 25% Dip In Price Shows Sentiment Is Matching Revenues

Is It Too Late To Consider Buying Omnicell, Inc. (NASDAQ:OMCL)?

Omnicell Is Building A Strong Moat

Consensus EPS estimates fall by 732%

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Omnicell, Inc. Reports Unaudited Impairment Changes Results for the Fourth Quarter Ended December 31, 2023

Omnicell, Inc. Provides Earnings Guidance for the First Quarter and Full Fiscal Year 2024

Omnicell, Inc. to Report Q4, 2023 Results on Feb 08, 2024

Does Omnicell (NASDAQ:OMCL) Have A Healthy Balance Sheet?

Omnicell, Inc. Announces Board Changes

Benign Growth For Omnicell, Inc. (NASDAQ:OMCL) Underpins Its Share Price

Is Omnicell, Inc. (NASDAQ:OMCL) Trading At A 48% Discount?

Omnicell, Inc. (NASDAQ:OMCL) Analysts Just Slashed Next Year's Revenue Estimates By 14%

Omnicell, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2023

Price target decreased by 28% to US$44.50

Third quarter 2023 earnings: EPS exceeds analyst expectations

Price target decreased by 7.7% to US$64.14

Omnicell, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Is There An Opportunity With Omnicell, Inc.'s (NASDAQ:OMCL) 27% Undervaluation?

Omnicell, Inc. Announces Board Changes

Now 20% undervalued after recent price drop

Would Omnicell (NASDAQ:OMCL) Be Better Off With Less Debt?

New minor risk - Shareholder dilution

Omnicell, Inc. Provides Earnings Guidance for the Third Quarter and Full Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Omnicell, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Omnicell, Inc. Appoints Bobby Ghoshal to Board of Directors

Why Omnicell, Inc. (NASDAQ:OMCL) Could Be Worth Watching

Founder recently bought US$295k worth of stock

A Look At The Fair Value Of Omnicell, Inc. (NASDAQ:OMCL)

Omnicell Announces Leadership and Organizational Changes

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Investors Could Be Concerned With Omnicell's (NASDAQ:OMCL) Returns On Capital

Is Omnicell (NASDAQ:OMCL) Using Too Much Debt?

At US$55.77, Is Omnicell, Inc. (NASDAQ:OMCL) Worth Looking At Closely?

Lead Independent Director exercised options and sold US$377k worth of stock

Full year 2022 earnings: EPS misses analyst expectations

Is There An Opportunity With Omnicell, Inc.'s (NASDAQ:OMCL) 42% Undervaluation?

Consensus EPS estimates fall by 19%

Omnicell, Inc. to Report Q4, 2022 Results on Feb 28, 2023

Returns On Capital Are Showing Encouraging Signs At Omnicell (NASDAQ:OMCL)